Investor Presentaiton
Diabetes care
Diabetes care sales in IO driven by both GLP-1 and insulin
9
Commercial execution and innovation
DKK billion
60
60
50
40
40
30
20
20
10
10
Diabetes care sales and growth in IO
5%
6%
10%
11%
14%
0
2017
Insulin
Novo NordiskⓇ
Must-win battles for IO
Drive insulin sales and patient base
TRESIBA
insulin degludec [rDNA origin] injection
37.7%
NN basal value
market share
RYZODEG
70% insulin degludec and 30% insulin aspart
[rDNA origin] injection
69.3%
NN mix value
market share
Drive GLP-1 market growth
OZEMPİC
semaglutide injection
RYBELSUS
semaglutide tablets
27
launch markets
59.4%
2018
2019
2020
2021
Injectable GLP-1
Oral GLP-1
Other Diabetes care
NN GLP-1 value market
share
Growth at CER
IO: International Operations; CER: Constant exchange rates; NN: Novo Nordisk
Source: Reported sales and growth at CER; IQVIA MAT value December 2021
CMD22
CAPITAL MARKETS DAYView entire presentation